natgillin/translations-raw huggingface dataset:
Significant benefit from maintenance treatment with MabThera was also seen for the secondary endpoints event-free survival (EFS), time to next anti-lymphoma treatment (TNLT) time to next chemotherapy (TNCT) and overall response rate (ORR) (Table 4).
Pomembna korist vzdrževalnega zdravljenja z zdravilom MabThera se je pokazala tudi pri sekundarnih opazovanih dogodkih – preživetju brez dogodkov (event-free survival – EFS), času do naslednjega zdravljenja limfoma (time to next anti-lymphoma treatment – TNLT), času do naslednje kemoterapije (time to next chemotherapy – TNCT) in celokupnem odgovoru (overall response rate – ORR) (preglednica 4).
Significant benefit from maintenance treatment with MabThera was also seen for the secondary endpoints event-free survival (EFS), time to next anti-lymphoma treatment (TNLT) time to next chemotherapy (TNCT) and overall response rate (ORR) (Table 5).
Pomembna korist vzdrževalnega zdravljenja z zdravilom MabThera se je pokazala tudi pri sekundarnih opazovanih dogodkih – preživetju brez dogodkov (event-free survival – EFS), času do naslednjega zdravljenja limfoma (time to next anti-lymphoma treatment – TNLT), času do naslednje kemoterapije (time to next chemotherapy – TNCT) in celokupnem odgovoru (overall response rate – ORR) (preglednica 5).
Significant cardiac dysfunction
Pomembna srčna disfunkcija
Significant cardiovascular disease, e.g. congestive heart failure (New York Heart Association Class II, III or IV), severe angina pectoris, cardiac arrhythmias, myocardial infarction within a 3 months period prior to treatment, venous thrombosis, occlusive peripheral arterial disease, recent pulmonary embolism.
Hujša srčnožilna bolezen, npr. zastojno srčno popuščanje (II., III. ali IV. razred po klasifikaciji New York Heart Association), huda angina pektoris, srčne aritmije, miokardni infarkt v obdobju 3 mesecev pred posegom, venska tromboza, okluzivna periferna arterijska bolezen, nedavna pljučna embolija
Significant decrease in plasma
Pri peroralni uporabi je mogoče
Significant decreases in plasma
Pričakuje se pomembno
Significant difference from placebo + MTX at the primary timepoint: ***p ≤0.0001
Značilna razlika v primerjavi s kombinacijo placebo + metotreksat ob času primarnega cilja preskušanja: ***p ≤ 0,0001
Significant difference from placebo at the primary time point: * p < 0.05, **p < 0.001 ***p ≤ 0.0001 MCID HAQ-DI ≥0.22, MCID SF-36 PHS >5.42, MCID SF-36 MHS >6.33
Značilna razlika v primerjavi s placebom ob času primarnega cilja študije: * p < 0,05; **p < 0,001; ***p ≤ 0,0001 MCID HAQ-DI ≥ 0,22; MCID SF-36 PHS > 5,42; MCID SF-36 MHS > 6,33
Significant Fab binding was also observed in the male reproductive tract (epididymis, sperm, seminal vesicle) and the skin.
Pomembno Fab vezavo so opažali tudi v moškem reproduktivnem sistemu (epididimisu, semenčicah, semenskih vrečkah) in koži.
Significant haematological dysfunction, e.g. leucocytes < 2.5 x 109/l, haemoglobin < 9 g/dl, platelets < 60 x 109/l, haemorrhagic diathesis or active bleeding disorder.
Hujše hematološke motnje, npr. levkociti < 2,5 x 109/l, hemoglobin < 9 g/dl, trombociti < 60 x 109/l, hemoragična diateza ali aktivna krvavitev
Significant improvement (p < 0.001) versus vehicle was seen in postmenopausal women.
Študije so pokazale statistično značilno izboljšanje (p < 0,001) pri postmenopavzalnih ženskah zdravljenih z zdravilom Vaniqa v primerjavi z vehiklom.
Significant improvement (p<0.01) in the 6MWD was demonstrated at week 12 when the patients were asked to delay taking study medicinal product in order to reflect trough active substance concentration.
Signifikantno izboljšanje (p<0.01) pri 6-minutnem testu hoje je bilo vidno v 12. tednu, ko je bilo bolnikom naročeno, naj odložijo odmerek študijskega zdravila, da bi se ugotovile najnižje koncentracije zdravilne učinkovine.
Significant improvement of signs of inflammation as measured by hs-CRP and MRI of both Sacroiliac Joints and the Spine was maintained in Humira-treated patients through Week 156 and Week 104, respectively.
Statistično izboljšanje znakov vnetja, merjenih s C-reaktivnim proteinom z veliko občutljivostjo (hs- CRP) in z magnetno resonanco (MRI) sakroiliakalnih sklepov in hrbtenice, se je ohranilo pri bolnikih, zdravljenih z zdravilom Humira, do 156. tedna oz. do 104. tedna, v tem zaporedju.
Significant improvements are seen in the pain, tender joint count, physical function (HAQ score), acute phase reactants and in the patient’s and physician’s global assessment.
Pomembno izboljšanje vidimo pri bolečini, številu občutljivih sklepov, telesnem funkcioniranju (lestvica HAQ), reaktantih akutne faze in globalni oceni tako bolnika kot zdravnika.
Significant improvements at Week 16 from baseline compared to placebo (Studies I and II) and MTX (Study II) were demonstrated in the DLQI (Dermatology Life Quality Index).
Značilno izboljšanje od izhodišča do 16. tedna se je v primerjavi s placebom (študiji I in II) in metotreksatom (študija II) izkazalo v dermatološkem indeksu kakovosti življenja (DLQI – Dermatology Life Quality Index).
Significant improvements were seen in physician’s clinical assessment of autoinflammatory disease activity: global assessment of autoinflammatory disease activity, assessment of skin disease (urticarial skin rash), arthralgia, myalgia, headache/migraine, conjunctivitis, fatigue/malaise, assessment of other related symptoms, and patient’s assessment of symptoms.
Pomembno izboljšanje so opažali pri zdravnikovi klinični oceni aktivnosti avotimunske bolezni: pri celotni oceni aktivnosti avtoimunske bolezni, pri oceni kožne bolezni (urtikarijski izpuščaj), artralgije, mialgije, glavobola/migrene, konjunktivitisa, utrujenosti/splošnega slabega počutja, pri oceni drugih povezanih simptomov in pri bolnikovi oceni simptomov.
Significant increase in blood pressure
pomembno zvišanje krvnega tlaka; nov napad migrenskega glavobola.
Significant increases in CD4+ and CD8+ T cell absolute counts, and percentages of lymphocytes, were observed with daratumumab treatment in peripheral whole blood and bone marrow.
Pri zdravljenju z daratumumabom so opažali pomembno zvišanje absolutnega števila CD4+ in CD8+ limfocitov T in njihovih odstotkov med vsemi limfociti v periferni krvi in kostnem mozgu.
Significant increases in plasma
Pričakovano je zvečanje
Significant inhibition of inflammatory signs in both sacroiliac joints and the spine was observed in the Cimzia- treated patients (all dose group), in the overall axial spondyloarthritis population as well as in the sub- populations of ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Pomembno zmanjšanje znakov vnetja sakroiliakalnih sklepov in hrbtenice so opazili pri bolnikih, ki so se zdravili z zdravilom Cimzia (skupina z vsemi odmerki), pri celotni populaciji z aksialnim spondiloartritisom in tudi v podpopulacijah z ankilozirajočim spondilitisom ter neradiografskim aksialnim spondiloartritisom.
significant lack of response to drugs used to treat anaemia; or
izrazito neodzivnost na zdravila za zdravljenje anemije.
Significant or unexplained hepatic dysfunction.
Pomembna ali nepojasnjena motnja delovanja jeter.
Significant positive effects were also noted for each subscale domain of the IIQ and for six of ten quality of life domains, including the incontinence impact domain, of the King’s Health Questionnaire (KHQ) as shown in the table below.
Pomembne pozitivne učinke so opazili tudi pri vseh podlestvicah vprašalnika IIQ in pri šestih izmed desetih domen kakovosti življenja vprašalnika King’s Health Questionnaire (KHQ), vključno z domeno vpliva inkontinence, kot je prikazano v preglednici spodaj.
Significant prolongation of the QT interval may occur when nilotinib is inappropriately taken with strong CYP3A4 inhibitors and/or medicinal products with a known potential to prolong QT, and/or food (see section 4.5).
Pri neustreznem sočasnem jemanju nilotiniba z močnimi zaviralci CYP3A4 in/ali z zdravili, za katera je znano, da lahko podaljšujejo interval QT, in/ali s hrano, lahko pride do pomembnega podaljšanja intervala QT (glejte poglavje 4.5).
Significant reduction in DAS28 from baseline (mean improvement) of 3.1–3.4 were observed in tocilizumab-treated patients compared to control patients (1.3-2.1).
Pri bolnikih, zdravljenih s tocilizumabom, so ugotovili značilno znižanje (povprečno izboljšanje) DAS28 za 3,1 do 3,4 od izhodišča v primerjavi s kontrolnimi bolniki (1,3 do 2,1).
Significant reductions in amprenavir Cmin
Opaženo bistveno zmanjšanje Cmin amprenavirja lahko pri bolnikih povzroči
Significant reductions in disability index (HAQ-DI) and fatigue (FACIT-Fatigue) scores were observed in patients treated with MabThera compared to patients treated with methotrexate alone.
Pri bolnikih, zdravljenih z zdravilom MabThera, so opazili značilna znižanja v indeksu nezmožnosti (HAQ-DI, Health Assessment Questionnaire Disability Index) in utrujenosti (FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy) v primerjavi z bolniki, ki so se zdravili le z metotreksatom.
Significant reductions in disability index (HAQ-DI) and fatigue (FACIT-Fatigue) were observed in patients treated with MabThera compared to patients treated with methotrexate alone.
Pri bolnikih, zdravljenih z zdravilom MabThera, so opazili značilna znižanja v indeksu nezmožnosti (HAQ-DI, Health Assessment Questionnaire Disability Index) in utrujenosti (FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy) v primerjavi z bolniki, ki so se zdravili le z metotreksatom.
Significant renal dysfunction, e.g. nephrotic syndrome, serum creatinine > 150 µmol/l, or creatinine clearance of < 50 ml/min.
Hujše motnje ledvičnega delovanja, npr. nefrotični sindrom, serumski kreatinin > 150 µmol/l ali kreatininski očistek < 50 ml/min
Significant respiratory depression.
Pomembna respiratorna depresija.
Significant response was first observed at Week 2 and maintained through 24 weeks (Table 10).
Značilen odziv so najprej opazili po 2 tednih in se je ohranil do 24. tedna (preglednica 10).
Significant response was first observed at Week 2 and maintained through 24 weeks (Table 8).
Značilen odziv so najprej opazili po 2 tednih in se je ohranil do 24. tedna (preglednica 8).
Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin, therefore, extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients.
Pri vseh živalskih vrstah, ki so bile izpostavljene ribavirinu, so dokazali pomembne teratogene in/ali embriocidne učinke, zato je potrebno izredno skrbno preprečevati nosečnost pri bolnicah in tudi pri partnerkah moških bolnikov.
Significant weight gain has been reported with INVEGA use.
Pri uporabi zdravila INVEGA so poročali o pomembnem zvečanju telesne mase.
Significant weight gain has been reported with TREVICTA use.
Pri uporabi zdravila TREVICTA so poročali o pomembnem zvečanju telesne mase.
Significant weight gain has been reported with Xeplion use.
Pri uporabi zdravila Xeplion so poročali o pomembnem zvečanju telesne mase.
Significantly decreased plasma concentrations of simeprevir are expected.
Pričakovano je pomembno zmanjšanje koncentracije simeprevirja v plazmi.
Significantly fewer patients in the abacavir group (9 patients, or 6 %) than in the nevirapine group (26 patients, or 17 %) or the efavirenz group (27 patients, or 17 %) discontinued the medicinal productbecause of adverse events.
V skupini z abakavirjem jih je značilno manj bolnikov (9 bolnikov ali 6 %) prenehalo jemati zdravilo zaradi neželenih učinkov kot v skupini z nevirapinom (26 bolnikov ali 17 %) ali efavirenzem (27 bolnikov ali 17 %).
Significantly fewer patients in the abacavir group (9 patients, or 6%) than in the nevirapine group (26 patients, or 17%) or the efavirenz group (27 patients, or 17%) discontinued the medicinal product because of adverse events.
V skupini z abakavirjem jih je značilno manj bolnikov (9 bolnikov ali 6 %) prenehalo jemati zdravilo zaradi neželenih učinkov kot v skupini z nevirapinom (26 bolnikov ali 17 %) ali efavirenzem (27 bolnikov ali 17 %).
Significantly fewer patients in the INTELENCE arm reached a clinical endpoint (AIDS-defining illness and/or death) as compared to the placebo arm (p = 0.0408).
V skupini, ki je prejemala zdravilo INTELENCE je statistično značilno manjše številu bolnikov doseglo opazovan dogodek (ki je bil določen kot razvoj AIDSa in/ali smrt), kot v skupini, ki je prejemala placebo (p = 0,0408).
Significantly greater improvements at Week 12 from baseline compared to placebo and etanercept were demonstrated in nail psoriasis (as measured by the Nail Psoriasis Severity Index [NAPSI]), in scalp psoriasis (as measured by Psoriasis Scalp Severity Index [PSSI]) and in palmoplantar psoriasis (as measured by Psoriasis Palmoplantar Severity Index [PPASI]).
Bistveno večja izboljšanja v 12. tednu od izhodišča so v primerjavi s placebom in etanerceptom dokazali pri psoriazi nohtov (merjeno z indeksom jakosti psoriaze nohtov NAPSI (Nail Psoriasis Severity Index)), psoriaze lasišča (merjeno z indeksom jakosti psoriaze lasišča PSSI (Psoriasis Scalp Severity Index)) in palmoplantarne psoriaze (merjeno z indeksom jakosti palmoplantarne psoriaze PPASI (Psoriasis Palmoplantar Severity Index)).
significantly increased.
povečana.
Significantly longer disease-free survival for the TAC arm compared to the FAC arm was demonstrated.
Preživetje brez bolezni je bilo v kraku TAC dokazano značilno daljše kot v kraku FAC.
Significantly more ciclosporin- treated patients (n = 13) required a switch to tacrolimus than tacrolimus-treated patients to ciclosporin (n = 2) (p = 0.02) (Keenan et al., Ann Thoracic Surg 1995;60:580).
S ciklosporina na takrolimus je moralo preiti statistično značilno več bolnikov (n = 13) kot s takrolimusa na ciklosporin (n = 2) (p = 0,02) (Keenan et al., Ann Thoracic Surg 1995;60:580).
Significantly more patients achieved HbA1c below 7% with liraglutide compared with exenatide (54.2% vs 43.4%, p=0.0015).
Z liraglutidom je HbA1c pod 7 % doseglo značilno več bolnikov kot z eksenatidom (54,2 % v prim. s 43,4 %, p = 0,0015).
Significantly more patients receiving 12.5 mg alogliptin and 1.000 mg metformin hydrochloride twice daily (59.5%) achieved target HbA1c levels of < 7.0% compared to those receiving either 12.5 mg alogliptin twice daily alone (20.2%, p<0.001) or 1,000 mg metformin hydrochloride twice daily alone (34.3%, p<0.001) at Week 26.
V 26. tednu je ciljne vrednosti HbA1c < 7,0 % doseglo pomembno več bolnikov, ki so prejemali alogliptin v odmerku 12,5 mg in metforminijev klorid v odmerku 1.000 mg dvakrat na dan (59,5 %), v primerjavi z bolniki, ki so prejemali samo alogliptin v odmerku 12,5 mg dvakrat na dan (20,2 %, p<0,001) ali samo metforminijev klorid v odmerku 1.000 mg dvakrat na dan (34,3 %, p<0,001).
Significantly more patients receiving 25 mg alogliptin (44.4%) achieved target HbA1c levels of  7.0% compared to those receiving placebo (18.3%) at Week 26 (p<0.001).
V 26. tednu je ciljne vrednosti HbA1c  7,0 % doseglo pomembno več bolnikov, ki so prejemali alogliptin v odmerku 25 mg (44,4 %), v primerjavi z bolniki, ki so prejemali placebo (18,3 %) (p<0,001).
Significantly more patients receiving 25 mg alogliptin (49.2%) achieved target HbA1c levels of  7.0% compared to those receiving placebo (34.0%) at Week 26 (p=0.004).
V 26. tednu je ciljne vrednosti HbA1c  7,0 % doseglo pomembno več bolnikov, ki so prejemali alogliptin v odmerku 25 mg (49,2 %), v primerjavi z bolniki, ki so prejemali placebo (34,0 %) (p=0,004).
Significantly more patients receiving 25 mg alogliptin plus 30 mg pioglitazone and metformin (33.2%) achieved target HbA1c levels of  7.0% compared to those receiving 45 mg pioglitazone and metformin (21.3%) at Week 52 (p<0.001).
V 52. tednu je ciljne vrednosti HbA1c  7,0 % doseglo pomembno več bolnikov, ki so prejemali alogliptin v odmerku 25 mg v kombinaciji s 30 mg pioglitazona in z metforminom (33,2 %), v primerjavi z bolniki, ki so prejemali 45 mg pioglitazona in metformin (21,3 %) (p<0,001).
Significantly more patients treated with Jakavi (20.9%) achieved a primary response (p<0.0001) compared to BAT (0.9%).
V skupini z zdravilom Jakavi je bil delež bolnikov, ki so dosegli primarni odziv, statistično značilno večji (20,9 %) v primerjavi z deležem takih bolnikov v skupini z najboljšim razpoložljivim zdravilom (0,9 %) (p<0,0001).
Significantly more placebo recipients flared during Period B (33/62; 53%) than those maintained on abatacept (12/60; 20%; chi-square p<0.001).
Med obdobjem B se je poslabšanje bolezni pojavilo pri pomembno večjem številu bolnikov, ki so prejemali placebo (33/62; 53%), kot pri tistih, ki so ostali na abataceptu (12/60; 20%; hi-kvadrat p<0,001).
Signifor 0.3 mg solution for injection
Signifor 0,3 mg raztopina za injiciranje
Signifor 0.3 mg solution for injection pasireotide
Signifor 0,3 mg raztopina za injiciranje pasireotid
Signifor 0.3 mg: One ampoule of 1 ml solution contains 0.3 mg pasireotide.
Signifor 0,3 mg: Ena ampula z 1 ml raztopine vsebuje 0,3 mg pasireotida.
Signifor 0.6 mg solution for injection
Signifor 0,6 mg raztopina za injiciranje
Signifor 0.6 mg solution for injection pasireotide
Signifor 0,6 mg raztopina za injiciranje pasireotid
Signifor 0.6 mg: One ampoule of 1 ml solution contains 0.6 mg pasireotide.
Signifor 0,6 mg: Ena ampula z 1 ml raztopine vsebuje 0,6 mg pasireotida.
Signifor 0.9 mg solution for injection
Signifor 0,9 mg raztopina za injiciranje
Signifor 0.9 mg solution for injection pasireotide
Signifor 0,9 mg raztopina za injiciranje pasireotid
Signifor 0.9 mg: One ampoule of 1 ml solution contains 0.9 mg pasireotide.
Signifor 0,9 mg: Ena ampula z 1 ml raztopine vsebuje 0,9 mg pasireotida.
Signifor 20 mg powder and solvent for suspension for injection
Signifor 20 mg prašek in vehikel za suspenzijo za injiciranje
Signifor 20 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection pasireotide
Signifor 20 mg prašek in vehikel za suspenzijo za injiciranje Signifor 40 mg prašek in vehikel za suspenzijo za injiciranje Signifor 60 mg prašek in vehikel za suspenzijo za injiciranje pasireotid
Signifor 40 mg and Signifor 60 mg are also available in multipacks containing 3 unit packs.
Zdravili Signifor 40 mg in Signifor 60 mg sta na voljo tudi v skupnih pakiranjih, ki vsebujejo po 3 posamična pakiranja.
Signifor 40 mg powder and solvent for suspension for injection
Signifor 40 mg prašek in vehikel za suspenzijo za injiciranje
Signifor 60 mg powder and solvent for suspension for injection
Signifor 60 mg prašek in vehikel za suspenzijo za injiciranje
Signifor contains less than 1 mmol sodium (23 mg) per dose, which means it is essentially “sodium-free”.
Zdravilo Signifor vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni, da je “brez natrija”.
Signifor controls over-production of cortisol.
Zdravilo Signifor uravnava prekomerno nastajanje kortizola.
Signifor has no or negligible effects on the ability to drive and use machines.
Zdravilo Signifor nima vpliva oziroma ima le zanemarljiv vpliv na sposobnost upravljanja vozil in strojev.
Signifor has no or negligible influence on the ability to drive and use machines.
Zdravilo Signifor nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Signifor intramuscular use 40 mg
Signifor intramuskularna uporaba
Signifor is also used for the treatment of adult patients with acromegaly when surgery has failed or is not an option and who are inadequately controlled with other medicines known as ‘somatostatin analogues’.
Uporablja se tudi za zdravljenje odraslih z akromegalijo, kadar kirurški poseg ni bil uspešen ali zanje ni primeren in pri katerih bolezni ni mogoče ustrezno obvladovati z drugimi zdravili, imenovanimi „analogi somatostatina“.
Signifor is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.
Zdravilo Signifor je indicirano za zdravljenje odraslih bolnikov z akromegalijo, za katere kirurški poseg ni primeren oziroma pri katerih kirurški poseg ni odpravil bolezni, pri tem pa bolezen ni ustrezno urejena z zdravljenjem z drugim analogom somatostatina.
Signifor is indicated for the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed.
Zdravilo Signifor je indicirano za zdravljenje tistih odraslih bolnikov s Cushingovo boleznijo, za katere kirurški poseg ni primeren oziroma pri katerih kirurški poseg ni bil uspešen.
Signifor is thus able to block the production of ACTH, helping to control the over-production of cortisol and improve the symptoms of Cushing’s disease.
Zdravilo Signifor tako lahko zavre tvorbo hormona ACTH, kar pomaga uravnavati prekomerno nastajanje kortizola in izboljša simptome Cushingove bolezni.
Signifor is used to treat adults with Cushing’s disease when surgery has failed or is not an option.
Zdravilo Signifor se uporablja za zdravljenje odraslih s Cushingovo boleznijo, pri katerih kirurški poseg ni bil uspešen ali zanje ni primeren.
Signifor may cause your blood sugar to increase.
Zdravilo Signifor vam lahko zviša koncentracijo sladkorja v krvi.
Signifor may lower your heart rate.
Zdravilo Signifor vam lahko upočasni srčni utrip.
Signifor powder is a slightly yellowish to yellowish powder in a vial.
Prašek zdravila Signifor je nekoliko rumenkast do rumenkast prašek v viali.
Signifor should not be used in patients with severe hepatic impairment (Child Pugh C) (see sections 4.3 and 4.4).
Zdravilo Signifor se ne sme uporabljati pri bolnikih s hudo okvaro jeter (Child Pugh stopnje C) (glejte poglavji 4.3 in 4.4).
Signifor solution for injection is a clear, colourless solution in an ampoule.
Signifor raztopina za injiciranje je bistra in brezbarvna raztopina v ampuli.
Signifor suspension must only be prepared immediately before administration.
Suspenzijo zdravila Signifor je treba pripraviti šele tik pred injiciranjem.
Signifor was also shown to be effective in reducing GH and IGF-1 levels in patients with acromegaly.
Zdravilo Signifor se je prav tako izkazalo za učinkovito pri zmanjševanju ravni GH in IGF-1 pri bolnikih z akromegalijo.
Signifor was shown to be effective in reducing cortisol levels in patients with Cushing’s disease.
Zdravilo Signifor se je izkazalo za učinkovito pri zmanjševanju koncentracije kortizola pri bolnikih s Cushingovo boleznijo.
Signifor was studied in 165 adult patients with Cushing’s disease where surgery was not appropriate.
Zdravilo Signifor so proučevali pri 165 odraslih bolnikih s Cushingovo boleznijo, za katere kirurški poseg ni bil primeren.
Signs and symptoms may include redness in the eye, pain in the eye, vision problems or blurry vision.
Znaki in simptomi lahko vključujejo rdečino oči, bolečino v očesu, težave z vidom ali zamegljen vid.
Signs and symptoms of a severe allergic reaction could include:
Znaki in simptomi hude alergijske reakcije bi lahko vključevali:
Signs and symptoms of a severe allergic reaction include:
Znaki in simptomi hude alergijske reakcije bi lahko vključevali:
Signs and symptoms of bleeding events might be haematoma of the skin, tar stools, blood in urine, nose bleed, etc.
Znaki in simptomi krvavitve so lahko podplutba na koži, smolnato blato, kri v seču, krvavitev iz nosu in nekateri drugi znaki.
Signs and symptoms of cardiac dysfunction such as dyspnoea, orthopnoea, increased cough, pulmonary oedema, S3 gallop, or reduced ventricular ejection fraction, have been observed in patients treated with Herceptin (see section 4.4).
Znake in simptome motenj v delovanju srca, kot so dispneja, ortopneja, povečan kašelj, pljučni edem, galop S3 ali zmanjšan ventrikularni srčni iztis so opazili pri bolnikih, zdravljenih z zdravilom Herceptin (glejte poglavje 4.4).
Signs and symptoms of dehydration, including renal impairment and acute renal failure have been reported in patients treated with liraglutide.
Znaki in simptomi dehidracije, vključno z okvaro ledvic in akutno odpovedjo ledvic, so bili opisani pri bolnikih, ki se zdravijo z liraglutidom.
Signs and symptoms of infection and sepsis.
znake in simptome okužbe in sepse,